Navigation Links
New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
Date:7/20/2009

CAPE TOWN, South Africa, July 20 /PRNewswire/ -- New data became available today at the 5(th) International AIDS Society Conference from ARTEN (Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine [Truvada(R)] versus Nevirapine). ARTEN is an open-label, multi-center and international non-inferiority clinical trial. It is the first large study to directly compare the efficacy and safety of nevirapine and ritonavir-boosted atazanavir (ATV/r) when combined with TDF/FTC, a modern backbone therapy commonly used with both nevirapine and ATV/r in clinical practice. All patients enrolled in the study had CD4+ cell counts as recommended in the prescribing information for nevirapine use (men <400 cells/mm3; women <250 cells/mm3). Nevirapine is marketed in the U.S. under the trademark name of Viramune(R) (nevirapine) tablets/oral suspension.

A total of 569 patients were in the study: 188 received once-daily nevirapine (400 mg), 188 received twice-daily nevirapine (200 mg) and 193 received ATV/r (300/100 mg once-daily). Nevirapine is not indicated for once-daily dosing. The safety and efficacy of once-daily dosing have not been established. All study participants also received tenofovir and emtricitabine (Truvada(R)).

The study's primary endpoint was virologic response at 48 weeks of treatment, with response defined as a viral load of <50 copies/mL measured at two consecutive visits prior to week 48 (i.e. suppression at weeks 24 and 36) and without subsequent rebound or change of therapy prior to week 48. In the primary analysis of the primary endpoint, the two nevirapine arms were combined. A non-inferiority endpoint with a two-tailed confidence interval of 5 percent within a 12 percent degree of certainty was applied. ARTEN follow-up is currently planned to continue for a total of 144 weeks.

"We're pleased to see th
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Aufgrund der enormen Nachfrage ... Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die Jahre 2014 ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und ... treten. Für international tätige Unternehmen geht ... "ob", sondern darum, "wann" sie die neu in ...
(Date:9/19/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... ITCA 650 (continuous subcutaneous delivery of exenatide) in type ... the 50 th Annual Meeting of the European ... the open-label, phase 3 FREEDOM-HBL (high baseline) trial showed ... poorly controlled type 2 diabetes. The results were presented ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014   ... of advanced cancer genome analysis and testing services, ... discovering and developing highly selective kinase inhibitors for ... genomic study of malignant mixed Mullerian tumors (MMMT), ... reproductive system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... SARcode Corporation presented data today for their lead investigational ... trial, subjects receiving SAR 1118 demonstrated a reduction in ... as compared to placebo. These data were part of ... Vision and Ophthalmology (ARVO) Annual Meeting held in Fort ...
... 3, 2011 At the Board of Directors meeting held ... per share. The dividend is payable on June 15, 2011 ... About Sigma-Aldrich: Sigma-Aldrich is a leading ... to Improve the Quality of Life. Its chemical and biochemical ...
Cached Medicine Technology:SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 2SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 3
(Date:9/21/2014)... September 21, 2014 “Cluster headaches are ... intense and difficult to resolve,” said Steve Young of ... think of a pain that is more intense.” , ... from cluster headaches, or migraines, that medical research is ... serotonin system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is ...
(Date:9/21/2014)... Viejo, California (PRWEB) September 21, 2014 ... X plugins have announced a new transition plugin ... “Transpack Vol. 3 delivers high quality transitions that will ... project,” said Christina Austin, CEO of Pixel Film Studios. ... 3 is a definite game changer.” , Transpack Vol. ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 C8 lawsuits ... of Ohio as the list of 20 possible ... narrowed down to six, reports Wright & Schulte LLC. ... from the almost 2500 C8 lawsuits filed that represent ... testicular cancer as a result of being exposed to ...
(Date:9/21/2014)... Top10BestSEOHosting.com, a leading review website, ... GreenGeeks are the most recommended hosting suppliers for ... quality hosting products. , “Don’t waste your ... recommend two great hosting companies to you,” the ... iPage and GreenGeeks are the most recommended suppliers ...
(Date:9/20/2014)... Recently, UWDress.com, a professional company of women’s ... its newly announced evening cocktail dresses . As ... occasion outfits are very popular among worldwide customers. Now, ... savings (up to 65 percent off). , All ... special occasion outfits for the global clients. The company ...
Breaking Medicine News(10 mins):Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Leading Review Website Top10BestSEOHosting.com Unveils The Best Hosting Suppliers In September 2Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2
... explain that a protein often called as the ‘fat ... ,The researchers from the University of Dundee ... cancer, diabetes and obesity. Dr Anil Mehta the head ... that the findings could improve the effectiveness of treatment ...
... reported the findings that adults in their seventies who drank ... live longer and have fewer heart attacks. ,The ... diseases in 1997 and 1998. The subjects were followed for ... consumption is associated with a 26% reduced risk of possible ...
... obsession of MP3 players that blare out music loudly is at ... generation.// Researchers from the Deafness Research, UK, found that 14 to ... 28 hours per week. ,Over a third of the ... sure sign of damage to hearing, after listening to loud music. ...
... to the investigations conducted by the General of ... tested positive for containing harmful drugs in erectile// ... ,After routine investigations Medsafe identified five remedies that ... individuals. Some contained sildenafil, the erectile dysfunction drug ...
... Australia's birth rate has risen since the government sang from ... the country" song sheet and began paying out 3,000 Australian// ... showed. ,But Treasurer Peter Costello wants to hear ... to "procreate and cherish" in order to reverse the declining ...
... care could cause a change in the role of district ... the roles of community health professionals such as health visitors ... affect about 9,000 nurses across Scotland. ,These were ... a major review of the community health sector for the ...
Cached Medicine News:Health News:Protein May Offer New Hope For Treatment Of Cystic Fibrosis 2Health News:Adults In Their Seventies Could Drink Alcohol To Help Against Heart Ailments 2Health News:Australia's Baby Bonus Plan has Increased the Birth Rate 2
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Liquichek Urinalysis Control is specifically designed for urine dipstick and microscopic testing. This control provides clear, visual positive and negative results, including hCG (pregnancy) and micr...
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Medicine Products: